1. Home
  2. AGEN

as 05-17-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Founded: 1994 Country:
United States
United States
Employees: N/A City: LEXINGTON
Market Cap: 224.7M IPO Year: 2000
Target Price: $116.50 AVG Volume (30 days): 762.6K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -12.64 EPS Growth: N/A
52 Week Low/High: $4.78 - $42.60 Next Earning Date: 05-07-2024
Revenue: $161,416,000 Revenue Growth: 69.94%
Revenue Growth (this year): 24.97% Revenue Growth (next year): 4.02%

Share on Social Networks:

Stock Insider Trading Activity of Agenus Inc. (AGEN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
ARMEN GARO H AGEN See Remarks Feb 15 '24 Buy $0.65 500,000 $324,050.00 625,969 SEC Form 4